Brief: Phio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762 Enhances Persistence Of T Cells For Tumor Cell Killing
22/09/2022 13:08
Sept 22 (Reuters) - Phio Pharmaceuticals Corp PHIO.O :
* PHIO PHARMACEUTICALS ANNOUNCES PRECLINICAL DATA
DEMONSTRATING
PH-762 ENHANCES PERSISTENCE OF T CELLS FOR TUMOR CELL KILLING AS
PRESENTED BY HELMHOLTZ MUNICH AT THE 9TH IMMUNOTHERAPY OF CANCER
CONFERENCE
Source text for Eikon: ID:nPnbsPfzZa
Further company coverage: PHIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing